Drug regulator in India orders clinical trials of generics

01/21/2013 | BioSpectrum Asia

The Drug Controller General of India, which regulates the country's pharmaceuticals, has asked drugmakers to conduct clinical trials of all generic drugs and seek approval within 18 months. The move is in response to abuse of legal loopholes that enabled some companies to bypass DGCI and sell drugs with dangerous side effects, many of which are banned abroad.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC